418 related articles for article (PubMed ID: 31188809)
1. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
Masarova L; Verstovsek S
Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
[TBL] [Abstract][Full Text] [Related]
2. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
4. Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Shide K; Takenaka K; Kitanaka A; Numata A; Kameda T; Yamauchi T; Inagaki A; Mizuno S; Takami A; Ito S; Hagihara M; Usuki K; Maekawa T; Sunami K; Ueda Y; Tsutsui M; Ando M; Komatsu N; Ozawa K; Kurokawa M; Arai S; Mitani K; Akashi K; Shimoda K
Ann Hematol; 2024 Jan; 103(1):97-103. PubMed ID: 37946031
[TBL] [Abstract][Full Text] [Related]
5. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.
Passamonti F; Mora B; Barraco D; Maffioli M
Curr Hematol Malig Rep; 2018 Jun; 13(3):173-182. PubMed ID: 29713873
[TBL] [Abstract][Full Text] [Related]
6. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
Masarova L; Alhuraiji A; Bose P; Daver N; Pemmaraju N; Cortes J; Pierce S; Kantarjian H; Verstovsek S
Eur J Haematol; 2018 Mar; 100(3):257-263. PubMed ID: 29226426
[TBL] [Abstract][Full Text] [Related]
7. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
8. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
9. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Hernández-Boluda JC; Pereira A; Gómez M; Boqué C; Ferrer-Marín F; Raya JM; García-Gutiérrez V; Kerguelen A; Xicoy B; Barba P; Martínez J; Luño E; Alvarez-Larrán A; Martínez-López J; Arbelo E; Besses C;
Haematologica; 2014 Apr; 99(4):e55-7. PubMed ID: 24488561
[No Abstract] [Full Text] [Related]
10. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
[TBL] [Abstract][Full Text] [Related]
11. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
12. Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.
Mora B; Passamonti F
Curr Hematol Malig Rep; 2022 Oct; 17(5):127-139. PubMed ID: 36048275
[TBL] [Abstract][Full Text] [Related]
13. Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis.
Li B; Gale RP; Xu Z; Qin T; Song Z; Zhang P; Bai J; Zhang L; Zhang Y; Liu J; Huang G; Xiao Z
J Hematol Oncol; 2017 May; 10(1):99. PubMed ID: 28464892
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Passamonti F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
[TBL] [Abstract][Full Text] [Related]
15. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
Martínez-Trillos A; Maffioli M; Colomer D; Alvarez-Larrán A; Pereira A; Angona A; Bellosillo B; Cervantes F
Ann Hematol; 2014 May; 93(5):797-802. PubMed ID: 24337516
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis.
Rontauroli S; Castellano S; Guglielmelli P; Zini R; Bianchi E; Genovese E; Carretta C; Parenti S; Fantini S; Mallia S; Tavernari L; Sartini S; Mirabile M; Mannarelli C; Gesullo F; Pacilli A; Pietra D; Rumi E; Salmoiraghi S; Mora B; Villani L; Grilli A; Rosti V; Barosi G; Passamonti F; Rambaldi A; Malcovati L; Cazzola M; Bicciato S; Tagliafico E; Vannucchi AM; Manfredini R
Blood Adv; 2021 Mar; 5(5):1452-1462. PubMed ID: 33666652
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Lussana F; Rambaldi A; Finazzi MC; van Biezen A; Scholten M; Oldani E; Carobbio A; Iacobelli S; Finke J; Nagler A; Volin L; Lamy T; Arnold R; Mohty M; Michallet M; de Witte T; Olavarria E; Kröger N
Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
[TBL] [Abstract][Full Text] [Related]
18. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
[TBL] [Abstract][Full Text] [Related]
20. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F; Giorgino T; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Caramazza D; Merli M; Pietra D; Casalone R; Rotunno G; Barbui T; Cazzola M; Vannucchi AM
Leukemia; 2017 Dec; 31(12):2726-2731. PubMed ID: 28561069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
